RecruitingPhase 3NCT07804186

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Sponsor

IDEAYA Biosciences

Enrollment

450 participants

Start Date

Sep 1, 2026

Study Type

INTERVENTIONAL

Conditions

Uveal Melanoma

Summary

This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Crizotinib (Xalkori) and a drug called Darovasertib for people with uveal melanoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDarovasertib

Oral, selectively targets key proteins

DRUGCrizotinib (Xalkori)

Oral small molecule

Locations(13)

Honor Health Research Institute

Scottsdale, Arizona, United States

UCLA Medical Center

Los Angeles, California, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Cancer Hematology Centers Western Michigan

Grand Rapids, Michigan, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Northwell Health

New York, New York, United States

Duke Cancer Center

Raleigh, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Wills Eye Hospital at Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Sarah Cannon Research Institute (SCRI)

Nashville, Tennessee, United States

University of Wisconsin Health

Madison, Wisconsin, United States

Universite de Montreal - Centre de Recherche du Centre Hospitalier de l'Universite de Montreal

Montréal, Ontario, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07804186

Related Trials

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

NCT056070952 locations

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT060700123 locations